flucytosine has been researched along with Disease Models, Animal in 65 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, the efficacy of amphotericin B and flucytosine in combination was investigated by mortality and fungal burden studies in a murine model of disseminated cryptococcosis using two clinical isolates of Cryptococcus neoformans, one susceptible and one resistant (i." | 7.73 | Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. ( Dannaoui, E; Dromer, F; Lortholary, O; Schwarz, P, 2006) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 7.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "The in vitro susceptibility of Candida albicans isolates to flucytosine was compared to therapeutic effect in experimental murine candidiasis (candidosis)." | 7.66 | Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. ( Bennett, JE; Polak, A; Scholer, HJ; Stevens, DA; Stiller, RL; Wall, M, 1983) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 5.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| " To evaluate the hypothesis that this discrepancy may be primarily due to the short half-life of 5-FC in mice, we compared the same total dosage of 75 mg of 5-FC per kg of body weight per day given by bolus injections or infused continuously via a subcutaneously implanted pump in immunosuppressed CF1 mice infected with C." | 5.29 | Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. ( Anaissie, EJ; Karyotakis, NC, 1996) |
| " The effect of neutropenia on the temporal profile of the burden of Candida albicans in untreated mice and those treated with amphotericin B was determined using a pharmacodynamic model of disseminated candidiasis." | 3.74 | Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. ( Denning, DW; Drusano, GL; Hope, WW; Louie, A; Moore, CB; Sharp, A; Walsh, TJ; Warn, PA, 2007) |
| " Thus, the efficacy of amphotericin B and flucytosine in combination was investigated by mortality and fungal burden studies in a murine model of disseminated cryptococcosis using two clinical isolates of Cryptococcus neoformans, one susceptible and one resistant (i." | 3.73 | Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. ( Dannaoui, E; Dromer, F; Lortholary, O; Schwarz, P, 2006) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 3.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "The in vitro susceptibility of Candida albicans isolates to flucytosine was compared to therapeutic effect in experimental murine candidiasis (candidosis)." | 3.66 | Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. ( Bennett, JE; Polak, A; Scholer, HJ; Stevens, DA; Stiller, RL; Wall, M, 1983) |
| " Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy." | 2.50 | Antifungal pharmacokinetics and pharmacodynamics. ( Andes, DR; Lepak, AJ, 2014) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 1.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| "CD-MSC toxicity on murine prostate cancer cells and tumour tropism were verified in vitro and ex-vivo before starting the preclinical studies." | 1.40 | Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. ( Abrate, A; Altaner, C; Benigni, F; Bettiga, A; Buono, R; Canu, T; Cavarretta, IT; Colciago, G; Del Maschio, A; Esposito, A; Guazzoni, G; Hedlund, P; Lucianò, R; Montorsi, F, 2014) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS." | 1.33 | Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006) |
| "75 mg/kg), administered singly or in combination with flucytosine (100 mg/kg)." | 1.31 | Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model. ( Ghannoum, MA; Hossain, MA; Long, L; Mukherjee, PK; Reyes, G, 2002) |
| "5-FC treatment of peritoneal carcinomatosis generated in syngeneic BDIX rats by CD-expressing DHD/K12 cells led to a complete and prolonged response and to prolonged survival." | 1.31 | Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. ( Bentires-Alj, M; Bours, V; Fillet, G; Gielen, J; Hellin, AC; Lechanteur, C; Lopez, M; Merville, MP; Princen, F, 2000) |
| "In mice bearing liver cancer, (60)Co-irradiated MM45T." | 1.31 | [Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes]. ( Chen, S; Sun, W; Tang, Y; Tang, Z; Wei, D, 2001) |
| " In situ transduction of the CD gene, followed by systemic use of 5-FC at a daily dosage of 300 mg/kg for 14 days, was performed two days later." | 1.31 | In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models. ( Yin, L; Zhang, Y; Zhang, Z; Zhao, F, 2002) |
| " Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of fluconazole as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of fluconazole was significantly more efficacious than a lower dose [P < 0." | 1.30 | Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. ( Graybill, JR; Najvar, LK; Nguyen, MH; Yu, CY, 1997) |
| " The dosing schedule required 30 days; neither addition of an enzyme inhibitor that increases the half-life of fluorocytosine nor intralumenal drug delivery is effective in shortening (to 15 days) the protocol." | 1.30 | Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy. ( Batra, RK; Boucher, RC; Hoganson, DK; Matsui, H, 1998) |
| "An orthotopic model of squamous cell cancer of the head and neck was used in vivo to study the CD/5-FC system both alone and with concurrent radiation due to the radiosensitizing properties that 5-FU generates in situ." | 1.30 | Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. ( Hamstra, DA; Oyedijo, D; Pu, A; Rehemtulla, A; Rice, DJ; Ross, BD, 1999) |
| "The growth of the human colon cancer cells was quantified by dot blot analysis of genomic DNA extracted from tumor-bearing liver, hybridized with a human-specific Alu probe." | 1.29 | Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. ( Crystal, RG; Hirschowitz, EA; Ohwada, A, 1996) |
| " To evaluate the hypothesis that this discrepancy may be primarily due to the short half-life of 5-FC in mice, we compared the same total dosage of 75 mg of 5-FC per kg of body weight per day given by bolus injections or infused continuously via a subcutaneously implanted pump in immunosuppressed CF1 mice infected with C." | 1.29 | Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. ( Anaissie, EJ; Karyotakis, NC, 1996) |
| " High-dose T-cin controls survived despite having received a cumulative dosage of more than twice the reported (LD(50)) mean lethal dose value." | 1.26 | Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo. ( Hariri, A; Larsh, HW; Sneller, MR; Sorenson, WG, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (9.23) | 18.7374 |
| 1990's | 13 (20.00) | 18.2507 |
| 2000's | 25 (38.46) | 29.6817 |
| 2010's | 20 (30.77) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Serena, C | 3 |
| Rodríguez, MM | 1 |
| Mariné, M | 4 |
| Pastor, FJ | 4 |
| Guarro, J | 4 |
| Verweij, PE | 1 |
| Te Dorsthorst, DT | 1 |
| Janssen, WH | 1 |
| Meis, JF | 1 |
| Mouton, JW | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Mitchell, LA | 1 |
| Lopez Espinoza, F | 3 |
| Mendoza, D | 2 |
| Kato, Y | 1 |
| Inagaki, A | 1 |
| Hiraoka, K | 2 |
| Kasahara, N | 6 |
| Gruber, HE | 5 |
| Jolly, DJ | 5 |
| Robbins, JM | 4 |
| Liu, S | 1 |
| Song, W | 1 |
| Liu, F | 1 |
| Zhang, J | 1 |
| Zhu, S | 1 |
| Hogan, DJ | 1 |
| Zhu, JJ | 1 |
| Diago, OR | 1 |
| Gammon, D | 1 |
| Haghighi, A | 1 |
| Lu, G | 1 |
| Das, A | 1 |
| Ostertag, D | 3 |
| Li, DD | 1 |
| Deng, L | 1 |
| Hu, GH | 1 |
| Zhao, LX | 1 |
| Hu, DD | 1 |
| Jiang, YY | 1 |
| Wang, Y | 1 |
| Dong, XY | 1 |
| Wang, WQ | 1 |
| Zhao, Y | 1 |
| Li, XD | 1 |
| Fang, ZG | 1 |
| Lin, DJ | 1 |
| Xiao, RZ | 1 |
| Huang, RW | 1 |
| Pan, GJ | 1 |
| Liu, JJ | 1 |
| Wang, L | 2 |
| Tang, Y | 3 |
| Eisner, W | 1 |
| Sparks, MA | 1 |
| Buckley, AF | 1 |
| Spurney, RF | 2 |
| Abrate, A | 1 |
| Buono, R | 1 |
| Canu, T | 1 |
| Esposito, A | 1 |
| Del Maschio, A | 1 |
| Lucianò, R | 1 |
| Bettiga, A | 1 |
| Colciago, G | 1 |
| Guazzoni, G | 1 |
| Benigni, F | 1 |
| Hedlund, P | 1 |
| Altaner, C | 1 |
| Montorsi, F | 1 |
| Cavarretta, IT | 1 |
| Lepak, AJ | 1 |
| Andes, DR | 1 |
| Huang, TT | 2 |
| Parab, S | 1 |
| Burnett, R | 2 |
| Diago, O | 1 |
| Hofman, FM | 1 |
| Espinoza, FL | 1 |
| Martin, B | 2 |
| Ibañez, CE | 3 |
| Pertschuk, D | 1 |
| Yagiz, K | 1 |
| Park, GT | 1 |
| Kim, SU | 2 |
| Choi, KC | 1 |
| Chung, T | 1 |
| Na, J | 1 |
| Kim, YI | 2 |
| Chang, DY | 1 |
| Kim, H | 1 |
| Moon, HE | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Chung, JK | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Paek, SH | 1 |
| Youn, H | 1 |
| Xing, L | 1 |
| Sun, X | 1 |
| Deng, X | 1 |
| Kotedia, K | 1 |
| Urano, M | 1 |
| Koutcher, JA | 1 |
| Ling, CC | 1 |
| Li, GC | 1 |
| Ito, S | 1 |
| Natsume, A | 1 |
| Shimato, S | 1 |
| Ohno, M | 1 |
| Kato, T | 1 |
| Chansakul, P | 1 |
| Wakabayashi, T | 1 |
| Hlavaty, J | 3 |
| Jandl, G | 2 |
| Liszt, M | 1 |
| Petznek, H | 2 |
| König-Schuster, M | 1 |
| Sedlak, J | 1 |
| Egerbacher, M | 1 |
| Weissenberger, J | 1 |
| Salmons, B | 2 |
| Günzburg, WH | 2 |
| Renner, M | 2 |
| Johnson, AJ | 1 |
| Ardiani, A | 1 |
| Sanchez-Bonilla, M | 1 |
| Black, ME | 1 |
| Kawasaki, Y | 1 |
| Tamamoto, A | 1 |
| Takagi-Kimura, M | 1 |
| Maeyama, Y | 1 |
| Yamaoka, N | 1 |
| Terada, N | 1 |
| Okamura, H | 1 |
| Kubo, S | 1 |
| Amundson, KK | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Daublebsky, V | 1 |
| Gunzburg, W | 1 |
| Orr, RY | 1 |
| Philip, N | 1 |
| Waters, AP | 1 |
| Holzmüller, H | 1 |
| Url, A | 1 |
| Berger, A | 1 |
| Howell, DN | 1 |
| Ruiz, P | 1 |
| Hossain, MA | 1 |
| Mukherjee, PK | 1 |
| Reyes, G | 1 |
| Long, L | 1 |
| Ghannoum, MA | 1 |
| Corban-Wilhelm, H | 1 |
| Hull, WE | 1 |
| Becker, G | 1 |
| Bauder-Wüst, U | 1 |
| Greulich, D | 1 |
| Debus, J | 1 |
| Schwarz, P | 1 |
| Dromer, F | 1 |
| Lortholary, O | 1 |
| Dannaoui, E | 1 |
| Graepler, F | 1 |
| Lemken, ML | 1 |
| Wybranietz, WA | 1 |
| Schmidt, U | 1 |
| Smirnow, I | 1 |
| Gross, CD | 1 |
| Spiegel, M | 1 |
| Schenk, A | 1 |
| Graf, H | 1 |
| Lauer, UA | 1 |
| Vonthein, R | 1 |
| Gregor, M | 1 |
| Armeanu, S | 1 |
| Bitzer, M | 1 |
| Lauer, UM | 1 |
| Goblirsch, M | 1 |
| Zwolak, P | 1 |
| Ramnaraine, ML | 1 |
| Pan, W | 1 |
| Lynch, C | 1 |
| Alaei, P | 1 |
| Clohisy, DR | 1 |
| Wang, W | 1 |
| Tai, CK | 2 |
| Kershaw, AD | 1 |
| Solly, SK | 1 |
| Klatzmann, D | 1 |
| Chen, TC | 1 |
| Eisold, S | 1 |
| Antolovic, D | 1 |
| Schmidt, J | 1 |
| Wiessner, R | 1 |
| Klar, E | 1 |
| von Knebel-Doeberitz, M | 1 |
| Linnebacher, M | 1 |
| Hope, WW | 1 |
| Drusano, GL | 1 |
| Moore, CB | 1 |
| Sharp, A | 1 |
| Louie, A | 1 |
| Walsh, TJ | 2 |
| Denning, DW | 1 |
| Warn, PA | 1 |
| Marimon, R | 1 |
| Wei, J | 1 |
| Wahl, J | 1 |
| Knauss, H | 1 |
| Zeller, S | 1 |
| Jarmy, G | 1 |
| Fitze, G | 1 |
| Debatin, KM | 1 |
| Beltinger, C | 1 |
| Kimura, T | 1 |
| Logg, CR | 1 |
| Haga, K | 1 |
| Lawson, GW | 1 |
| Stiller, RL | 1 |
| Bennett, JE | 1 |
| Scholer, HJ | 1 |
| Wall, M | 1 |
| Polak, A | 1 |
| Stevens, DA | 1 |
| Ponnuvel, KM | 1 |
| Rama, CP | 1 |
| Menon, T | 1 |
| Ohwada, A | 1 |
| Hirschowitz, EA | 1 |
| Crystal, RG | 1 |
| Karyotakis, NC | 1 |
| Anaissie, EJ | 1 |
| Nguyen, MH | 1 |
| Najvar, LK | 2 |
| Yu, CY | 1 |
| Graybill, JR | 3 |
| Yao, YM | 1 |
| Lu, LR | 1 |
| Yu, Y | 1 |
| Liang, HP | 1 |
| Chen, JS | 1 |
| Shi, ZG | 1 |
| Zhou, BT | 1 |
| Sheng, ZY | 1 |
| Ding, JC | 1 |
| Bauer, M | 1 |
| Diamond, DM | 1 |
| Leal, MA | 1 |
| Johnson, D | 1 |
| Williams, BK | 1 |
| Thomas, AM | 1 |
| Najvar, L | 1 |
| Larsen, RA | 1 |
| Hoganson, DK | 1 |
| Matsui, H | 1 |
| Batra, RK | 1 |
| Boucher, RC | 1 |
| Hamstra, DA | 1 |
| Rice, DJ | 1 |
| Pu, A | 1 |
| Oyedijo, D | 1 |
| Ross, BD | 1 |
| Rehemtulla, A | 1 |
| Bentires-Alj, M | 1 |
| Hellin, AC | 1 |
| Lechanteur, C | 1 |
| Princen, F | 1 |
| Lopez, M | 1 |
| Fillet, G | 1 |
| Gielen, J | 1 |
| Merville, MP | 1 |
| Bours, V | 1 |
| Pierrefite-Carle, V | 4 |
| Gavelli, A | 4 |
| Brossette, N | 4 |
| Baqué, P | 4 |
| Benchimol, D | 4 |
| Bourgeon, A | 4 |
| Staccini, P | 4 |
| Rossi, B | 4 |
| Mala, M | 1 |
| Saint-Paul, MC | 2 |
| Chazal, M | 1 |
| Milano, G | 1 |
| Gugenheim, J | 1 |
| Huguet, C | 1 |
| Barchiesi, F | 1 |
| Schimizzi, AM | 1 |
| Bocanegra, R | 1 |
| Caselli, F | 1 |
| Di Cesare, S | 1 |
| Giannini, D | 1 |
| Di Francesco, LF | 1 |
| Giacometti, A | 1 |
| Carle, F | 1 |
| Scalise, G | 1 |
| Sun, W | 1 |
| Tang, Z | 1 |
| Wei, D | 1 |
| Chen, S | 1 |
| Bi, Y | 1 |
| Gao, J | 1 |
| Xu, D | 1 |
| Saint Paul, MC | 1 |
| Zhang, Z | 1 |
| Yin, L | 1 |
| Zhang, Y | 1 |
| Zhao, F | 1 |
| Sande, MA | 1 |
| Bowman, CR | 1 |
| Calderone, RA | 1 |
| Sneller, MR | 1 |
| Hariri, A | 1 |
| Sorenson, WG | 1 |
| Larsh, HW | 1 |
| Hamilton, JD | 1 |
| Elliott, DM | 1 |
| Bava, AJ | 1 |
| Negroni, R | 1 |
| Heidemann, HT | 1 |
| Brune, KH | 1 |
| Sabra, R | 1 |
| Branch, RA | 1 |
| Singh, SM | 1 |
| Sharma, S | 1 |
| Chatterjee, PK | 1 |
| Skosyreva, AM | 1 |
| Baklanova, OV | 1 |
| Padeĭskaia, EN | 1 |
| Aoki, S | 1 |
| Mechinaud, F | 1 |
| Bacher, J | 1 |
| Lee, J | 1 |
| Rubin, M | 1 |
| Pizzo, PA | 1 |
| Ackerbauer, H | 1 |
| Meingassner, JG | 1 |
| Mieth, H | 1 |
| O'Day, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flucytosine and Disease Models, Animal
| Article | Year |
|---|---|
Antifungal pharmacokinetics and pharmacodynamics.
Topics: Animals; Antifungal Agents; Disease Models, Animal; Echinocandins; Flucytosine; Humans; Mice; Mycose | 2014 |
1 trial available for flucytosine and Disease Models, Animal
| Article | Year |
|---|---|
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucyt | 2018 |
63 other studies available for flucytosine and Disease Models, Animal
| Article | Year |
|---|---|
Combined therapies in a murine model of blastoschizomycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Colony Count, Microbial; Disease Models, Animal; Drug Sy | 2007 |
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
Topics: Animals; Animals, Outbred Strains; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease | 2008 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model | 2017 |
Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Flow Cytom | 2018 |
Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Disease Models, Animal; Fluconazole; F | 2013 |
Antibody-directed double suicide gene therapy targeting of MUC1- positive leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Proliferation; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Gan | 2013 |
Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice.
Topics: Albuminuria; Animals; Antimetabolites; Cytosine Deaminase; Diabetic Nephropathies; Disease Models, A | 2014 |
Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression.
Topics: Adenocarcinoma; Animals; Cell Movement; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Gen | 2014 |
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos | 2015 |
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Diseas | 2016 |
Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-β against Lymph Node-Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell- and Tissue-Based Therapy; Colore | 2017 |
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cytosine Deaminase; Dihydrouracil Dehy | 2016 |
Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana.
Topics: Amphotericin B; Animals; Antifungal Agents; Ascomycota; Disease Models, Animal; Drug Therapy, Combin | 2009 |
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells.
Topics: Animals; Blotting, Western; Bystander Effect; Cell Line, Tumor; Coculture Techniques; Cytosine Deami | 2009 |
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma.
Topics: Animals; Bystander Effect; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flu | 2010 |
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Topics: Animals; Brain Neoplasms; Bystander Effect; Cytosine Deaminase; Disease Models, Animal; Drug Evaluat | 2011 |
Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
Topics: Animals; Artificial Gene Fusion; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Flucy | 2011 |
Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma.
Topics: Adult; Animals; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; G | 2011 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Improved negative selection protocol for Plasmodium berghei in the rodent malarial model.
Topics: Administration, Oral; Animals; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Mala | 2012 |
Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.
Topics: Animals; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzym | 2012 |
A novel mouse model of podocyte depletion.
Topics: Acute Kidney Injury; Animals; Antimetabolites; Cytosine Deaminase; Disease Models, Animal; Flucytosi | 2012 |
Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; | 2002 |
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Disease Models, Anima | 2002 |
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcosis; Cryptococcus neoformans; Disease | 2006 |
Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Anim | 2005 |
Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Topics: Animals; Antimetabolites; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Cytosine Deaminase; | 2006 |
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep | 2006 |
Combined antifungal therapy in a murine infection by Candida glabrata.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida glabrata; Candidiasis; Colony Count, Microbial; | 2006 |
Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.
Topics: Adenoviridae; Animals; Apoptosis; CD4-Positive T-Lymphocytes; Cytosine Deaminase; Cytotoxicity, Immu | 2006 |
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; D | 2007 |
Effect of antifungal treatment in a murine model of blastoschizomycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Disease Models, Animal; Dose-Response Relationship, Drug | 2007 |
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Caspases; Cell Division; Cell Line, Tumor; Cloning, Molecular; | 2007 |
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Topics: Animals; Colorectal Neoplasms; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Fluo | 2007 |
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model.
Topics: Animals; Candida albicans; Candidiasis; Cytosine; Disease Models, Animal; Dose-Response Relationship | 1983 |
Systemic and gastrointestinal candidiasis of infant mice as model for antifungal therapy.
Topics: Amphotericin B; Animals; Candidiasis; Disease Models, Animal; Fluconazole; Flucytosine; Fungemia; Ga | 1993 |
Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Cell Division; Colonic Neoplasms; Cytosine Deami | 1996 |
Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis.
Topics: Animals; Antifungal Agents; Candidiasis; Disease Models, Animal; Flucytosine; Immunosuppressive Agen | 1996 |
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; Dose-Response Re | 1997 |
Influence of selective decontamination of the digestive tract on cell-mediated immune function and bacteria/endotoxin translocation in thermally injured rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Translocation; Burns; Cell Division; Cells, Cultured; Coli | 1997 |
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Cryptococcus neoformans; Disease Models, Animal; Drug Evalu | 1997 |
Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy.
Topics: Adenocarcinoma; Animals; Cell Division; Cytosine Deaminase; Disease Models, Animal; Escherichia coli | 1998 |
Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Division; Combined Modality | 1999 |
Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Colorectal Neoplasms; Cytosine Deami | 2000 |
Re: Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer Vaccines; Colonic Neoplasms; Cytosine Deaminase; Di | 2000 |
[Vaccination by suicide gene therapy against a model of hepatic metastasis from colon cancer in the rat].
Topics: Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Disease Models, Animal; Flucytosine | 2000 |
Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Colony Count, Microbial; Cryptococcosis; Cryptococcus neoformans; Diseas | 2001 |
[Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes].
Topics: Animals; Carcinoma, Hepatocellular; Combined Modality Therapy; Cytosine Deaminase; Disease Models, A | 2001 |
[Therapeutic effect of 5-fluorocytosine on cytosine deaminase gene transduced Wilms' tumor xenograft in nude mice].
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cytosine Deaminase; Disease Models, Animal; Flucyto | 2000 |
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Bystander Effect; Colonic Neoplasms; Cytosine Deaminase; D | 2002 |
In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
Topics: Adenoviridae; Animals; Cell Division; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Lymph | 2002 |
Naked DNA injection for liver metastases treatment in rats.
Topics: Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Disease Models, Animal; Flucytosine | 2002 |
Experimental Candida albicans endocarditis: characterization of the disease and response to therapy.
Topics: Agglutinins; Amphotericin B; Animals; Antibodies, Fungal; Aortic Valve; Candida albicans; Candidiasi | 1977 |
Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
Topics: Amphotericin B; Animals; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Cytosine; Disease Mo | 1977 |
Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
Topics: Amphotericin B; Animals; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Cytosine; Disease Mo | 1975 |
Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 1992 |
Acute and chronic effects of flucytosine on amphotericin B nephrotoxicity in rats.
Topics: Amphotericin B; Animals; Disease Models, Animal; Drug Combinations; Drug Interactions; Flucytosine; | 1992 |
Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Corneal Ulcer; Disease Model | 1990 |
[Pathomorphological estimation of models of mouse Candida infection induced by intravenous or intracerebral contamination].
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Candidiasis; Colony Count, Microbial; Disease Mod | 1990 |
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.
Topics: Acute Disease; Agranulocytosis; Amphotericin B; Animals; Candidiasis; Chronic Disease; Disease Model | 1990 |
[Experimental renal infection with Aspergillus fumigatus in mice: a chemotherapeutic model of an organic mycosis].
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease Models, An | 1985 |
Studies in experimental keratomycosis.
Topics: Adrenal Cortex Hormones; Animals; Antifungal Agents; Candidiasis; Cornea; Corneal Diseases; Disease | 1985 |